Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Exelixis initiation details — Buy at Needham; tgt $28 (21.20)Needham initiates EXEL with a Buy and price target of $28. Since 2010 Exelixis has focused internal resources on commercializing cabozantinib in oncology. With two approvals now under its belt, and firm believes several more to come, Exelixis looks poised to turn profitable. Shared profits from a second partnered asset, cobimetinib, should help accelerate the process. As profits grow, <strong>they expect co to invest to become a LT growth story in oncology through measured investment in R&D and the potential acquisition of leveragable assets. Despite strong performance in EXEL over the last 12 months, firm believes the growth story at Exelixis is just beginning.</strong></td> </tr></table>"